Articles

Emerald Health Pharmaceuticals is a science-based company.  Our team of scientists, along with researchers from collaborating organizations, have published many scientific articles in high-quality, peer-reviewed journals regarding our proprietary cannabinoid-derived therapies.

Multiple Sclerosis

Cannabidiol and Other Cannabinoids in Demyelinating Diseases”. Int J Mol Sci. (2021) Mar 15;22(6):2992. DOI: 10.3390/ijms22062992. Authors: Navarrete C, García-Martín A, Rolland A, DeMesa J, Muñoz E.

Effects of EHP-101 on inflammation and remyelination in murine models of multiple sclerosis”. Neurobiol Dis. (2020) Sep;143:104994. DOI: 10.1016/j.nbd.2020.104994. Authors: Navarrete C, García-Martin A, Garrido-Rodríguez M, Mestre L, Feliú A, Guaza C, Calzado MA, Muñoz E.

Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy” Journal of Neuroinflammation (2018) 15:64 DOI 10.1186/s12974-018-1103-y Authors: Carmen Navarrete, Francisco Carrillo-Salinas, Belén Palomares, Miriam Mecha, Carla Jiménez-Jiménez, Leyre Mestre, Ana Feliú, Maria L. Bellido, Bernd L. Fiebich, Giovanni Appendino, Marco A. Calzado, Carmen Guaza and Eduardo Muñoz

A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis”. PLoS One (2014) 9(4): e94733, DOI: 10.1371/journal.pone.0094733. Authors: Francisco J. Carrillo-Salinas, Carmen Navarrete, Mirian Mecha M, Ana Feliú, Juan A. Collado, Irene Cantarero, Maria L. Bellido, Eduardo Muñoz and Carmen Guaza.

A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis”. Journal of Neuroimmune Pharmacology. (2012) 4:1002-1016, DOI: 10.1007/s11481-012-9399-3. Authors: Aitor G. Granja, Francisco Carrillo-Salinas, Alberto Pagani, María Gómez-Cañas, Roberto Negri, Carmen Navarrete, Miriam Mecha, Leyre Mestre, Bernd L. Fiebich, Irene Cantarero, Marco A. Calzado, Maria L. Bellido, Javier Fernandez-Ruiz, Giovanni Appendino, Carmen Guaza and Eduardo Muñoz.

Scleroderma

Cannabinoids in Metabolic Syndrome and Cardiac Fibrosis”. Curr Hypertens Rep. (2020) Oct 21;22(12):98. DOI: 10.1007/s11906-020-01112-7. Authors: Navarrete C, Garcia-Martin A, DeMesa J, Muñoz E.

Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for systemic sclerosis”. Biochemical Pharmacology (2019) 163:321-334 DOI: 10.1016/j.bcp.2019.02.029. Authors: Adela García-Martín, Martín Garrido-Rodríguez, Carmen Navarrete, Diego Caprioglio, Belén Palomares, Jim DeMesa, Alain Rolland, Giovanni Appendino, and Eduardo Muñoz

The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders”. Biochemical Pharmacology (2018) Nov;157:122-133. DOI: 10.1016/j.bcp.2018.08.022. Authors: Río CD, Millán E, García V, Appendino G, DeMesa J, Muñoz E.

VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2-receptor-dependent pathways”. Br J Pharmacol. (2018) Oct;175(19):3813-3831. DOI: 10.1111/bph.14450. Authors: Del Rio C, Cantarero I, Palomares B, Gómez-Cañas M, Fernández-Ruiz J, Pavicic C, García-Martín A, Luz Bellido M, Ortega-Castro R, Pérez-Sánchez C, López-Pedrera C, Appendino G, Calzado MA, Muñoz E.

EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis”. Biochemical Pharmacology (2018) 157:304-313, DOI: 10.1016/j.bcp.2018.07.047. Authors: Adela García-Martín, M. Garrido-Rodríguez, Carmen Navarrete, Carmen Del Río C, Maria L. Bellido, Giovanni Appendino, Marco A. Calzado and Eduardo Muñoz.

The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways”. Scientific Report (2016) 6:21703, DOI. 10.1038/srep21703. Authors: Carmen del Río, Carmen Navarrete, Juan A. Collado, M. Luz Bellido, María Gómez-Cañas, M. Ruth Pazos, Javier Fernández-Ruiz, Federica Pollastro, Giovanni Appendino, Marco A. Calzado, Irene Cantarero and Eduardo Muñoz.

Parkinson’s Disease

Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease“. Molecules (2021) May 28;26(11):324. Authors: Burgaz S, García C, Gómez-Cañas M, Rolland A, Muñoz E, Fernández-Ruiz J.

Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its. analogs CBGA-Q and CBGA-Q-Salt in Parkinson’s disease using 6-hydroxydopamine-lesioned mice”. Mol Cell Neuroscience (2021) Jan;110:103583. DOI: 10.1016/j.mcn.2020.103583. Authors: Burgaz S, García C, Gómez-Cañas M, Navarrete C, García-Martín A, Rolland A, Del Río C, Casarejos MJ, Muñoz E, Gonzalo-Consuegra C, Muñoz E, Fernández-Ruiz J.

Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor”. Journal of Neuroinflammation (2018) 15:19 DOI 10.1186/s12974-018-1060-5 Authors: Concepción García, María Gómez-Cañas, Sonia Burgaz, Belén Palomares, Yolanda Gómez-Gálvez, Cristina Palomo-Garo, Sara Campo, Joel Ferrer-Hernández, Carolina Pavicic, Carmen Navarrete, M. Luz Bellido, Moisés García-Arencibia, M. Ruth Pazos, Eduardo Muñoz and Javier Fernández-Ruiz

Development of An oral treatment with the PPAR-γ-acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson’s disease”. Molecules (2019) 24(15). pii: E2702, DOI: 10.3390/molecules24152702. Authors: Sonia Burgaz, Concepción García, Maria Gómez-Cañas, Eduardo Muñoz and Javier Fernández-Ruiz.

Huntington’s Disease

“VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s disease” . Scientific Report (2016) July 19;6:29789. Authors: Javier Díaz-Alonso, Juan Paraíso-Luna, Carmen Navarrete, Carmen del Río, Irene Cantarero, Belén Palomares, José Aguareles, Javier Fernández-Ruiz, María Luz Bellido, Federica Pollastro, Giovanni Appendino, Marco A. Calzado, Ismael Galve-Roperh, Eduardo Muñoz.

Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration” Translational Neurodegeneration (2019) 8:9 DOI:10.1186/s40035-019-0148-x Authors: José Aguareles, Juan Paraíso-Luna, Belén Palomares, Raquel Bajo-Grañeras, Carmen Navarrete, Andrea Ruiz-Calvo, Daniel García-Rincón, Elena García-Taboada, Manuel Guzmán, Eduardo Muñoz and Ismael Galve-Roperh

Other

“VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity”.

Scientific Report (2018) Oct 31;8(1):16092. DOI: 10.1038/s41598-018-34259-0. Authors: Palomares B, Ruiz-Pino F, Navarrete C, Velasco I, Sánchez-Garrido MA, Jimenez-Jimenez C, Pavicic C, Vazquez MJ, Appendino G, Bellido ML, Calzado MA, Tena-Sempere M, Muñoz E.

Posters